--Scopus BioPharma Inc. today announced that it has filed an amendment to the Current Report on Form 8- K that was filed by the Company on December 27, 2021 with the U.S. Securities and Exchange ...

Scopus BioPharma’s Pure Play Immuno-Oncology Subsidiary, Duet BioTherapeutics, Independently Valued at $25 Million Scopus Maintains Approximately 90% Ownership Stake in Duet ...

Scopus BioPharma Inc. is a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need. Scopus currently conducts substantially all of ...

Today, investors in Scopus Biopharma (NASDAQ: SCPS) and SCPS stock are seeing incredible gains. This stock has moved more than 115% higher at the time of writing on extremely heavy volume.

Check out our SCPS stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.

News provided by Scopus BioPharma Inc. Nov 07, 2023, 9:15 AM ET DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma Data Suggests ...

On Thursday, shares of Scopus Biopharma I (NASDAQ: SCPS) experienced volatile short activity. After the activity, the stock price went up +44.85% to $0.3401. The overall sentiment for SCPS has ...

Short interest in Scopus BioPharma Corp (OOTC:SCPS) decreased during the last reporting period, falling from 280.30M to 275.20M. This put 1.17% of the company's publicly available shares short.

News provided by Scopus BioPharma Inc. Nov 07, 2023, 9:15 AM ET DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma Data Suggests ...

Review Scopus BioPharma Inc (SCPS:PINX) stock and the current sustainability and ESG risk rating to help with your investing decisions.